Company Overview and News
SYDNEY, Jan 9 (Reuters) - London copper inched up in early trade on Tuesday as an advancing U.S. dollar lost steam, while Shanghai copper recovered from a drop in the previous session to trade marginally higher.
BEIJING (Reuters) - As China tightens restrictions on imports of foreign waste, Chinese metal recyclers and even smelters like Jiangxi Copper Co are increasingly looking to use Southeast Asian countries as an alternative location for the processing of copper scrap.
Over 270 ETFs were launched in 2017 and many are in the pipeline waiting for approval. But investors must be knowing that not all get to see the same success after months of trading. Some die an early death while some keep getting fuller with assets over time. Below we highlight a few new ETFs that may see smooth trading in 2018 and make a killing (read: 7 Successful New ETFs of 2017).
Chicago, IL – Jan 03, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cambria Value and Momentum ETF (VAMO - Free Report) , PowerShares S&P 500 Value With Momentum (SPVM - Free Report) , Schwab 1000 Index ETF (SCHK - Free Report) , IQ Chaikin U.
After a great 2017 (for stocks), investors will now be mulling over what’s in store for this year. Chances are high that optimism will be quelled a bit. Trump bump is largely baked in now and the Fed is less likely to cause much upheaval this year. The global economy including the United States has picked up momentum.
Copper rose to its highest point in nearly four years last week following further curbs on domestic production in China, closing at new year-to-date high for 2017. LME and Comex copper continued its longest bull run in more than a year, after closing at its highest level since January 2014 on December 22.
BEIJING (Reuters) - China’s copper smelters on Friday lowered the floor for their treatment and refining charges (TC/RCs) in the first quarter of 2018 by 8.4 percent, signaling tighter supply of copper concentrate in the first three months of the New Year.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Copper prices rallied to a near four-year high on Dec 27, 2017, driven by strong demand from the world’s largest consumer and robust global economic growth.
Copper prices extended their longest winning streak to a 10th day to send London’s mega miners to the top of the FTSE 100 for a second straight day.
Country Garden leads Hong Kong-listed developers on strong sales while Kweichow Moutai surges after raising prices of its fiery liquor.
Copper has rallied for 15 consecutive sessions; seems mostly like a demand story, but Chinese supply constraints too.
The FTSE 100 and 250 hit fresh all-time records on a subdued return to trading as supply squeezes boosted copper and oil prices to multi-year highs.
Gold futures managed a slim advance Wednesday but were headed for what would be their best finish in roughly a month, accumulating a fifth-straight day of gains while metals and other commodities attracted global investor interest as 2018 dawns.
Copper prices leapt to three-and-a-half-year peaks on Wednesday after a jump in China's imports of the metal in November boosted expectations of stronger demand from the top consumer.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...